FDA Approves Label Expansion for ARS Pharmaceuticals' neffy Nasal Spray

ARS Pharmaceuticals (SPRY) has received FDA approval to remove the age requirement for its neffy 1 mg epinephrine nasal spray. The regulatory update allows the needle-free treatment to be administered to pediatric patients based on weight rather than age. Previously, the label required children to weigh at least 33 lbs in addition to meeting specific age criteria. This label expansion is expected to significantly broaden the addressable market for the company's primary product. By removing age-based restrictions, ARS Pharmaceuticals can now offer its emergency allergy treatment to a wider demographic of younger children. Market analysts view this as a positive regulatory milestone that strengthens SPRY's competitive position in the epinephrine delivery market.

Sources:globenewswire.comhcplive.comconexiant.combenzinga.commarketscreener.comdrugtopics.comempr.commorningstar.comsnacksafely.com